Teva Pharmaceutical Industries Ltd (TEVA) shares are soaring 8.65% in intraday trading on Wednesday following the release of its better-than-expected first-quarter 2025 earnings report and raised full-year guidance. The world's largest generic drugmaker demonstrated resilience in a challenging market environment, buoyed by strong sales of its branded drugs.
Teva reported adjusted earnings of $0.52 per share for the quarter ended March 31, surpassing the analysts' consensus estimate of $0.46. This represents a notable increase from $0.48 per share in the same quarter last year. The company's revenue rose 1.9% to $3.89 billion, slightly below the expected $3.99 billion, but still showing growth in a competitive market landscape.
The earnings beat was primarily driven by strong sales gains in Teva's trio of branded drugs treating migraines, Huntington's disease, and schizophrenia. This performance underscores the company's successful diversification strategy beyond its core generic drug business. Furthermore, Teva has updated its full-year 2025 guidance, now expecting non-GAAP diluted EPS of $2.45 to $2.65, up from its previous forecast of $2.35 to $2.65. The company also narrowed its revenue guidance to $16.8 billion to $17.2 billion, considering the current market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.